Dr Bruce Chabner joins Peregrine as clinical advisor
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals (US) has elected cancer researcher Dr Bruce Chabner as a clinical advisor on the design of clinical trials for its bavituximab cancer programme. Dr Chabner is clinical director of the Massachusetts General Hospital (MGH) Cancer Center, chief of haematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before that, he had a 25-year career at the National Cancer Institute, including serving as scientific director and director of the division of cancer treatment.